Darolutamide (Nubeqa): Prostate Cancer Landscape After ESMO 2026

Darolutamide, sold as Nubeqa, is an oral androgen receptor inhibitor developed by Bayer and Orion for prostate cancer. On October 24, 2026, the DASL-HiCaP trial was presented at the ESMO Congress in Madrid, taking the drug into a new, earlier-stage setting: very high-risk localized prostate cancer treated with radiotherapy.

Mechanism at a glance

Prostate cancer cells depend on male hormones signaling through the androgen receptor. Darolutamide blocks that receptor and is taken as two 300 mg tablets twice daily with food, always alongside androgen deprivation therapy (ADT). Its label warnings include ischemic heart disease, seizure and embryo-fetal toxicity.

Why it matters

Approved uses. In the US, darolutamide was approved for non-metastatic castration-resistant prostate cancer (FDA, July 30, 2019). On August 5, 2022 it was approved with docetaxel for metastatic hormone-sensitive disease based on ARASENS (1,306 patients; overall survival HR 0.68). On June 3, 2025 the FDA approved it with ADT, without chemotherapy, for metastatic castration-sensitive disease based on ARANOTE (669 patients; radiographic progression-free survival HR 0.54, with no statistically significant overall survival gain at the final analysis, HR 0.78). Orion and Bayer say it is approved in more than 85 markets.

What DASL-HiCaP reported. Tamim Niazi (McGill University) presented the interim analysis (abstract LBA4, Presidential Symposium I). It enrolled 1,106 patients with localized, very high-risk disease, randomized to darolutamide or placebo for 96 weeks on top of 96 weeks of ADT plus radiotherapy. The reported figures:

• Metastasis-free survival (conventional imaging): HR 0.42 (95% CI 0.27 to 0.66; P = .0001). Four-year rates were 95% vs 88%.
• PSA progression-free survival: HR 0.47; four-year rates 91% vs 83%.
• Overall survival: 21 vs 24 deaths (HR 0.88, 95% CI 0.49 to 1.59), and prostate cancer-specific survival HR 0.58. Both are immature with wide uncertainty.
• Safety: no new signals reported. Grade 3 or higher adverse events were 43% vs 36%.

This was an interim analysis, triggered at 87 of the 130 planned events. The sources we found (company release and OncLive coverage) do not mention a peer-reviewed publication, and Bayer and Orion state darolutamide is not currently approved in this setting. No regulatory submission was announced in the sources we reviewed.

Competitive pressure points

• Enzalutamide (Xtandi): approved by the FDA on November 16, 2023 for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (EMBARK). In localized disease with radiotherapy, the ENZARAD trial (802 patients) shows no posted results on ClinicalTrials.gov.
• Apalutamide (Erleada): approved for non-metastatic castration-resistant (February 2018) and metastatic castration-sensitive disease (September 2019). On May 31, 2026, Johnson & Johnson reported PROTEUS, apalutamide plus ADT before and after prostatectomy, with a metastasis-free survival HR of 0.80 (published in NEJM); it has not been approved in that setting. Its ATLAS trial with radiotherapy (1,503 patients) lists an estimated primary completion of March 2027.
• Different surgical and radiation settings: DASL-HiCaP tests a radiotherapy population, while PROTEUS tests surgery, so the two readouts address different patients.
• Context: for the broader treatment pathway, see our treatment algorithm guide.

What to watch

• Whether Bayer and Orion file for the localized indication, and what regulators make of an interim analysis with immature survival data.
• The final DASL-HiCaP analysis (planned at 130 events) and survival follow-up.
• ATLAS and ENZARAD readouts, which would show whether rival drugs repeat the benefit with radiotherapy.
• Whether adding 96 weeks of therapy in earlier disease changes treatment duration norms.

Recent developments

Updated November 4, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Oct 24, 2026: Orion and Bayer reported DASL-HiCaP: a 58% lower risk of metastasis or death (HR 0.42). (Orion release via Nasdaq) Detailed figures were reported by OncLive.
• May 31, 2026: J&J reported PROTEUS for apalutamide in the perioperative setting. (J&J)
• Jun 3, 2025: FDA approved darolutamide with ADT for metastatic castration-sensitive prostate cancer. (The ASCO Post)
• Aug 5, 2022: FDA approved darolutamide with docetaxel. (The ASCO Post)

Upcoming catalysts

• Not yet dated: final DASL-HiCaP analysis; the registry lists estimated primary completion of January 2028 (ClinicalTrials.gov).
• March 2027 (estimated): primary completion of ATLAS.

Bottom line

Darolutamide is an established player in advanced prostate cancer, and DASL-HiCaP is its first positive Phase 3 in earlier disease. The metastasis-free survival result is strong, but survival data are immature and the readout is interim. Rival apalutamide and enzalutamide programs are pressing in the same earlier settings.

For how to read the trial records behind these dates, see how to read a ClinicalTrials.gov record.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.